Reading this field well comes down to one habit: place a claim in the hierarchy of evidence before reacting to it. A blinded, controlled study can establish cause; an observational survey shows association; an anecdote describes one experience; marketing exists to persuade. [1] Systematic review The emerging science of microdosing: A systematic review of research on low dose psychedelics (1955-2021) and recommendations for the field doi:10.1016/j.neubiorev.2022.104706 In microdosing specifically, blinding is decisive, because the phenomenon is so vulnerable to expectation — the self-blinding study erased much of the apparent benefit once expectation was controlled. [2] Clinical trial Self-blinding citizen science to explore psychedelic microdosing doi:10.7554/eLife.62878 Anecdotes are hypotheses, not proof; marketing collapses the four distinctions on purpose. This is the on-ramp; Foundations goes deeper. [3] Peer-reviewed Microdosing psychedelics: More questions than answers? An overview and suggestions for future research doi:10.1177/0269881119857204
Education-only. Not medical advice. This teaches source literacy; it makes no claim about whether microdosing works for you.
A reading toolkit, not a verdict. The goal is to judge claims accurately, wherever they land.
The hierarchy, and what each level can establish
The most useful question to ask of any claim is not “is it positive?” but “what kind of evidence is this, and what can that kind show?”
| Source | Can establish | Cannot establish |
|---|---|---|
| Blinded controlled study | Whether the intervention caused the effect | Much on its own without replication |
| Observational survey | Associations and patterns | That the practice caused the outcome |
| Anecdote | That an experience occurred | That it generalises or was caused by the drug |
| Marketing | What is being sold | Anything reliable about efficacy |
Surveys repeatedly show microdosers report benefits, but their design cannot separate the practice from the people who self-select into it. [4] Observational A systematic study of microdosing psychedelics doi:10.1371/journal.pone.0211023 That is not a flaw to overlook; it is the boundary of what the method can say.
Why blinding is decisive here
Microdosing is unusually exposed to expectation, and blinding is what separates a drug effect from an expectation effect. When people know whether they took the substance, expectation contaminates the result. The self-blinding study controlled for exactly this and found much of the apparent benefit appeared under placebo too. [2] Clinical trial Self-blinding citizen science to explore psychedelic microdosing doi:10.7554/eLife.62878 So in this field, “was it blinded?” is often the question that decides whether a finding means anything about the compound.
Spotting marketing dressed as evidence
Marketing has tells: a product attached to the claim, mechanism language used as proof, testimonials standing in for data, and full-dose research repurposed to sell microdosing. It tends to collapse the four distinctions deliberately — mechanism into result, report into outcome, plausibility into proof. When a claim has something to sell and leans on those moves, treat it as persuasion until independent evidence supports it.
Anecdotes in their proper place
Anecdotes are valuable as hypotheses and as accounts of lived experience; they are not evidence of cause or generalisability. Held there, they enrich understanding; mistaken for data, they mislead. The same discipline lets you see why legality is not evidence of safety or efficacy either — different system, different question.
Marketing can use real science selectively
Marketing does not always make false claims; more often it uses true facts selectively and lets the reader infer more than the evidence shows. A quick claim audit defuses most of it.
| Claim type | What to ask |
|---|---|
| ”Research shows…” | Which study? What substance, dose, and outcome? |
| ”Clinically studied…” | Was it microdosing, or full-dose treatment? |
| ”Natural support…” | Does natural origin say anything about safety or efficacy? |
| ”Users report…” | Were there controls, blinding, and a comparison group? |
| ”Helps focus or mood” | Was that outcome pre-defined and tested against placebo? |
- Hierarchy first
- Ask what kind of evidence a claim is before judging it. [1] Systematic review The emerging science of microdosing: A systematic review of research on low dose psychedelics (1955-2021) and recommendations for the field doi:10.1016/j.neubiorev.2022.104706
- Blinding decides
- It separates a drug effect from an expectation effect. [2] Clinical trial Self-blinding citizen science to explore psychedelic microdosing doi:10.7554/eLife.62878
- Survey limits
- Associations are not causes; self-selection confounds. [4] Observational A systematic study of microdosing psychedelics doi:10.1371/journal.pone.0211023
- Marketing tells
- A sale plus collapsed distinctions signals persuasion, not data.
Frequently asked questions
How do I tell a strong source from a weak one?
Look at what kind of evidence it is and what that kind can establish. A controlled, blinded study can show whether an intervention caused an effect; an observational survey can show associations but not cause; an anecdote can show that an experience occurred but nothing about whether it generalises; and marketing exists to persuade, not to inform. Placing a claim in this hierarchy before reacting to it is the single most useful habit for reading this field.
Why is blinding such a big deal in this area specifically?
Because microdosing is unusually vulnerable to expectation, and blinding is what separates a drug effect from an expectation effect. When people know whether they took the substance, their expectations contaminate the result; the self-blinding study showed that controlling for this erased much of the apparent benefit. [2] Clinical trial Self-blinding citizen science to explore psychedelic microdosing doi:10.7554/eLife.62878 So in this field, whether a study was blinded is often the difference between a finding that means something about the compound and one that mostly reflects belief.
How do I spot marketing dressed up as evidence?
Watch for the tells: a product or service attached to the claim, mechanism language used as if it were proof, testimonials standing in for data, and citations to full-dose research repurposed to sell microdosing. Marketing tends to collapse the four distinctions on purpose — turning a mechanism into a result, a report into an outcome, plausibility into proof. When a claim has something to sell and leans on those moves, treat it as persuasion until independent evidence backs it.
Are anecdotes worthless then?
No — anecdotes are valuable as hypotheses and as descriptions of lived experience; they are simply not evidence of cause or generalisability. A vivid account can tell you something is worth investigating and what it felt like to one person. The error is treating it as proof that the same thing will happen for you or for people in general. Held in their proper place, anecdotes enrich understanding; mistaken for data, they mislead.
Is there a companion article that goes deeper?
Yes. Foundations has a dedicated article on how to read microdosing claims, which applies these source-literacy ideas directly to the kinds of claims you will encounter, and the research-literature article surveys what the studies themselves look like. This getting-started article is the on-ramp; those go further. Reading them together gives you a durable toolkit for evaluating anything you come across, on this topic or adjacent ones.